Survival in HIV-infected patients is associated with hepatitis C virus infection and injecting drug use since the use of highly active antiretroviral therapy in the Lyon observational database.
Highly active antiretroviral therapy (HAART) has reduced the incidence of death in HIV-infected patients but various rates of survival have been reported due to the infection with hepatitis C virus (HCV) and the use of injecting drugs (IDU). A survival analysis was performed to estimate and compare the death rates in HIV-positive patients infected by IDU and/or positive for HCV antibodies in the pre-HAART and HAART periods in Lyon (France) between 1992 and 2002. Patients were stratified into four groups (G): HCV-/IDU-(G1), HCV+/IDU-(G2), HCV+/IDU-(G3), HCV+/IDU+ (G4) and adjusted death rates in the pre-HAART era (< 1996) and the HAART era (> or = 1996) were compared. The aHR of progression to death was 1.05 (95% CI 0.75-1.47, P = 0.75) for G2, 1.09 (95% CI 0.54-2.22, P = 0.81) for G3 and 0.90 (95% CI 0.65-1.24, P =0.51) for G4 compared with G1 in the pre-HAART era. The aHR of progression to death was 0.76 (95% CI 0.28-2.08, P = 0.59) for G2, 1.23 (95% CI 0.17-8.86, P = 0.84) for G3 and 2.90 (95% CI 1.62-5.20, P < 0.001) for G4, compared with G1 in the HAART era. HAART management of HCV+/IDU+ patients needs to be optimized for them to achieve a similar benefit as observed among other individuals.
Voirin
N
N
Laboratory of Epidemiology and Public Health and INSERM U271, Lyon, France.
Trépo
C
C
Miailhes
P
P
Touraine
J L
JL
Chidiac
C
C
Peyramond
D
D
Livrozet
J M
JM
Ritter
J
J
Chevallier
P
P
Fabry
J
J
Allard
R
R
Vanhems
P
P
D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D015331:Cohort Studies; D018450:Disease Progression; D005260:Female; D005602:France; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy / Q000453:epidemiology / Q000401:mortality*; D006526:Hepatitis C / Q000150:complications* / Q000453:epidemiology / Q000401:mortality*; D018937:Hepatitis C Antibodies / Q000097:blood; D006801:Humans; D008297:Male; D015819:Substance Abuse, Intravenous / Q000150:complications* / Q000453:epidemiology / Q000401:mortality*; D016019:Survival Analysis
D018937:Hepatitis C Antibodies